Chairman Address to 2023 Annual General Meeting

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, herein provides the Chairman Address to the 2023 Annual General Meeting (AGM) of shareholders to be held today at the at the offices of BDO Australia – Melbourne, Collins Square, Tower 4/727 Collins St, Docklands, Victoria at 3.30pm AEDT.

Chairman Address to Shareholders

The agenda for the Meeting today will be as follows: I will start by providing a brief overview of Neurotech, our key highlights from the 2023 financial year, our corporate governance activities and outlook. I will then outline the Meeting procedures and continue to the formal items of business.

Following the completion of the formal items, Executive Director Dr Tom Duthy will then give a presentation of Neurotech's core development platform, clinical trials, strategic initiatives and our outlook for the 2024 financial year.

The 2023 financial year was one of substantial progress for Neurotech. We focused our commercial strategy on the development of NTI164, our broad spectrum cannabinoid drug product, for paediatric neurological patients where neuroinflammatory processes are a hallmark of their disease. This revised strategy was strongly supported by existing and new investors, including a number of Australian and overseas institutional investors, with the Company completing a $9.0 million capital raise in September 2022, despite a very challenging and capital constrained biotech market.

Our first clinical trial was a world-first study in paediatric autism spectrum disorder (ASD) patients. The Company completed its Phase I/II trial in ASD and reported very significant results at 20 weeks and again at 52 weeks, with NTI164 showing clinically meaningful improvements in these patients across a large number of clinically validated assessment measures. As a result, we initiated a larger, Phase II/III trial during the year, the results of which will be available in the first quarter of calendar year 2024 (Q1 CY2024). We intend to progress discussions with the Therapeutic Goods Administration regarding requirements for future approval of NTI164 for ASD in Australia.

In Australia, one in 50 people have ASD and 34% of patients currently enrolled into the National Disability Insurance Scheme (NDIS) have autism. We estimate the costs of managing these patients at $6.1 billion annually and growing. Hence, a cost-effective intervention like NTI164 has the potential to not only improve patient outcomes but drive societal and taxpayer benefits through lower ancillary costs such as occupational therapies.

In parallel to our ASD program, during the year the Company initiated a Phase I/II clinical trial in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and announced plans for a new trial in Rett syndrome. I am pleased to say we recently reported the PANDAS/PANS results to the market, and in rapid fashion have completed recruitment for the Phase I/II Rett Syndrome trial. Like ASD, the Rett Syndrome data is also expected in Q1 CY2024 and represents a multi-billion dollar market opportunity.

PANDAS/PANS is a challenging, abrupt onset disorder of children with no approved treatments, limited clinical trials and an urgent medical need. Therefore, it represents an exciting development

opportunity for the Company. Our Phase I/II results showed material improvements over time with statistically significant and clinically meaningful improvements in our two key primary measures of severity of illness and anxiety/depression. All patients remain on treatment. We are the first Company to show such a positive benefit with a broad spectrum cannabinoid therapy.

For both PANDAS/PANS and Rett Syndrome, our strategy is to seek Orphan Drug Designations in both Europe and the US for these rare disorders. Securing an ODD will add significant value to our programs, through various financial incentives but more importantly 7 years market exclusivity in the US and 10 years in Europe. This will create a strong competitive advantage for NTI164.

Our 2023 R&D incentive rebate of $3.17 million was received yesterday. When coupled with our 30 September cash balance of $2.9 million, our pro-forma cash position of approximately $6.1 million is sufficient to complete all current clinical trials for NTI164 and to advance our regulatory plans for 2024.

I would like to acknowledge the contribution of Professor Allan Cripps AO, Neurotech's Non-Executive Director and Chief Scientist, who was a vocal proponent of our science and clinical trial programs in paediatric neurological disorder patients and sadly passed away in late December 2022.

Finally, on behalf of the Board of Directors, we thank our paediatric patients, their caregivers, our clinicians and our committed shareholders for their support of Neurotech over the last year. We remain very excited by the prospects for our Company this financial year and look forward to updating our various stakeholders on our clinical and regulatory developments across these important paediatric neurological disorders, where progress to date has been excellent.

Authority
This announcement has been authorised for release by the Chairman of Neurotech International Limited.

Further Information
Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company has commenced a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD and additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit http://www.neurotechinternational.com.